BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2022 9:25:37 AM | Browse: 456 | Download: 1537
 |
Received |
|
2021-10-21 14:53 |
|
Peer-Review Started |
|
2021-10-21 14:55 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-02 08:56 |
|
Revised |
|
2021-12-15 14:01 |
|
Second Decision |
|
2022-02-15 03:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-02-16 07:18 |
|
Articles in Press |
|
2022-02-16 07:18 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-02-17 07:03 |
|
Publish the Manuscript Online |
|
2022-02-22 09:25 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mitchell L Ramsey, Michael R Wellner, Kyle Porter, Stephen E Kirkby, Susan S Li, Luis F Lara, Sean G Kelly, A James Hanje and Lindsay A Sobotka |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lindsay A Sobotka, Consultant, Assistant Professor, Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, 410 West 10th Avenue, Columbus, OH 43210, United States. lindsay.sobotka@osumc.edu |
| Key Words |
Cirrhosis; Ursodiol; Transmembrane; Cystic fibrosis; Market scan; Cystic fibrosis related liver disease |
| Core Tip |
The effect of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on hepatobiliary outcomes in cystic fibrosis (CF) patients remains unknown. Utilizing a nationwide database, the incidence of cirrhosis in CF patients utilizing CFTR modulators, ursodiol, combination therapy or neither therapy was compared. A total of 7201 patients were studied including 12.6% on a CFTR modulator, 7.0% on ursodiol, 6.1% on combination therapy and 74.3% on neither therapy. Patients taking CFTR modulators had a lower incidence of cirrhosis than untreated patients (P = 0.05), or patients treated with Ursodiol (P < 0.001) or Ursodiol and CFTR modulators (P = 0.003). CFTR modulators may reduce the incidence of cirrhosis in patients with CF. |
| Publish Date |
2022-02-22 09:25 |
| Citation |
Ramsey ML, Wellner MR, Porter K, Kirkby SE, Li SS, Lara LF, Kelly SG, Hanje AJ, Sobotka LA. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World J Hepatol 2022; 14(2): 411-419 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i2/411.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i2.411 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
